OakChart

BriaCell Therapeutics Corp

BCTXHealthcare·Biotechnology·Canada·Nano·NASD·Nov 11 • 3:59 PM ET

3.59-0.10 (-2.71%)
2026-11-12 02:16 CET
Market cap
31.35 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-34.90 USD m
Free cash flow, TTM
-28.56 USD m
EPS diluted, TTM
-9.33
P/E
-
Compare

Price

BCTX against its 20, 50 and 200-day averages
2050200earnings
4.006.004.4M8.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BCTXclose 3.5920-day 3.4450-day 3.72200-day 3.773.5952w low

72.6% under the 52-week high of 13.09 on 9 Dec 2025. 52-week low 2.60 on 11 Jun 2026. Last 15 sessions, 38.3% high to low

Volume 0.22× normal · the line is the 50-bar volume average

Profile

BCTX
52-week range, 9% of the way up
2.6013.09

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Employees31
IPOOct 28, 2010
Beta1.26
ATR, 14d0.28
Rel volume0.22
Short float9.26%
Insider own0.15%
Inst own13.32%

Snapshot

6 groups

Valuation

Index-
Market Cap31.34M
Enterprise Value9.96M
Income-34.90M
Sales0.00M
Book/sh1.88
Cash/sh2.35
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees31
IPOOct 28, 2010

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.91
P/C1.53
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.76
Current Ratio2.76
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-9.33
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y67.06% 56.72%
Sales past 3/5Y- -
EPS Y/Y TTM87.83%
Sales Y/Y TTM-
EPS Q/Q67.06%
Sales Q/Q-
EarningsJun 10 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own0.15%
Insider Trans0.00%
Inst Own13.32%
Inst Trans1.48%
ROA-154.34%
ROE-203.63%
ROIC-212.82%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.24%
SMA50-3.46%
SMA200-4.85%
Trades-

Technical

Shs Outstand8.73M
Shs Float8.72M
Short Float9.26%
Short Ratio3.15
Short Interest0.81M
52W High13.09 -72.57%
52W Low2.60 38.08%
Volatility11.18% 8.32%
ATR (14)0.28
RSI (14)50.80
Beta1.26
Rel Volume0.22
Avg Volume256.66K
Volume56,054

Performance

Perf Week12.54%
Perf Month-3.23%
Perf Quarter4.36%
Perf Half Y-14.11%
Perf YTD-49.51%
Perf Year-65.94%
Perf 3Y-99.39%
Perf 5Y-99.76%
Perf 10Y-99.95%
Recom1.00
Target Price150.00
Prev Close3.69
Price3.59
Change %-2.71%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Feb 14, 2022InitiatedHH.C. WainwrightBuy$25+596.4%

Peers

Mkt cap
TickerCompanyMkt cap
GLSIGreenwich LifeSciences Inc236.17M
ELTXElicio Therapeutics Inc46.14M
SLSSELLAS Life Sciences Group Inc1.70B
ATOSAtossa Therapeutics Inc20.26M
PDSBPDS Biotechnology Corp107.11M
IMMPImmutep Limited ADR26.24M
IMNNImunon Inc4.04M
MAIAMAIA Biotechnology Inc63.60M
AIMAIM ImmunoTech Inc5.93M
GOVXGeovax Labs Inc1.10M

News

latest 14 of 200
  • BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 (GlobeNewswire) +20.80%
  • BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 (GlobeNewswire)
  • BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer (GlobeNewswire)
  • BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting (GlobeNewswire)
  • Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study (GlobeNewswire)
  • BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center (GlobeNewswire)
  • BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone (InvestorsHub) -14.99%
  • BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+ (GlobeNewswire)
  • BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer (GlobeNewswire)
  • BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer (GlobeNewswire)
  • BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT (GlobeNewswire) +6.49%
  • BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT (GlobeNewswire)
  • BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT (GlobeNewswire)
  • BriaCell Therapeutics Announces Closing of Offering (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-06-10-0.990--23.3000.00--
2026Q22026-03-10-2.580--2.5770.00--
2026Q12025-12-11-4.350--4.3510.00--
2025Q42025-10-15-12.110-12.110-4.2950.000.001
2025Q32025-06-16-16.400-17.600-16.4020.000.001
2025Q22025-03-12-23.300-19.400-23.3050.000.001
2025Q12024-12-11-33.000-12.000-32.6690.000.001
2024Q42024-10-24-10.500-78.000-10.1030.000.001
2024Q32024-06-1716.500-82.50016.1040.000.001
2024Q22024-03-19-106.5-30.000-106.010.000.001
2024Q12023-12-15-75.000-27.000-74.4890.000.001
2023Q42023-10-25-23.250-64.500-22.7010.000.001
2023Q32023-09-21-48.000-47.775-47.3210.000.002
2023Q22023-03-16-114.39-52.740-114.850.000.002
2023Q12022-12-14-10.500-49.500-10.6970.000.001
2022Q42022-10-27-156.75-45.750-157.50.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-13.365--458.550.00-
2022FY-257.01-151.53-259.830.000.00
2023FY-195-238.5-194.970.000.00
2024FY-45.000-162-43.6790.000.00
2025FY-62.190-2.955-0.000.00
2026FY-6.970--0.00-
2027FY--3.400--10.10
2028FY--1.560--35.40
2029FY--0.740--73.00
2030FY-0.580--122.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2025-10-271000.000.000.00
2026Q4S2025-10-261000.000.000.00
2026Q4S2025-10-251000.000.000.00
2026Q4S2025-10-241000.000.000.00
2026Q4S2025-10-231000.000.000.00
2026Q4S2025-10-221000.000.000.00
2026Q4S2025-10-211000.000.000.00
2026Q4S2025-10-201000.000.000.00
2026Q4S2025-10-191000.000.000.00
2026Q4S2025-10-181000.000.000.00
2026Q4S2025-10-171000.000.000.00
2026Q4S2025-10-161000.000.000.00
2026Q4S2025-10-151000.000.000.00
2026Q4S2025-10-141000.000.000.00

Estimate history

EPS, annual-1413.118-1132.078-771.861-458.546-259.83-194.97-43.679-62.186-6.966
Period201820192020202120222023202420252026
EPS, quarterly-10.103-32.669-23.305-16.402-4.295-4.351-2.577-0.988-1.415
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual000000000
Period201820192020202120222023202420252026
Sales, quarterly000000000
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual0.0040.0040.0050.1020.1030.1070.1221.8848.708
Period201820192020202120222023202420252026
Shares, quarterly0.1220.2410.2950.6561.8841.8847.257.258.708
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.120.110.080.020.020.020.010.01
Gross Profit-0.12-0.12-0.11-0.08-0.02-0.02-0.02-0.01-0.01
Selling, General and Administrative Excl. Other35.9335.9327.1033.2523.2615.276.963.584.69
Research and Development29.1329.1321.2727.1815.348.022.022.213.72
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-36.05-36.05-27.20-33.33-23.27-15.29-6.98-3.60-4.70
Interest Expense0.000.000.040.000.000.000.080.030.02
Unusual Expense-0.50-0.41-0.81-28.24-2.1211.654.590.06-0.32
Net Income Before Taxes-35.33-35.33-26.56-4.93-20.30-26.84-13.82-3.67-4.38
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-35.33-35.33-26.56-4.93-20.30-26.84-13.82-3.67-4.38
Net Income From Continuing Operations-34.90-34.90-26.31-4.79-20.30-26.84-13.82-3.67-4.38
Net Income-34.90-34.90-26.31-4.79-20.30-26.84-13.82-3.67-4.38
EPS (Recurring)-4.05-7.02-63.53-223.90-209.22-180.85-351.98-763.21-1,189.76
EPS (Basic, Before Extraordinaries)-9.33-6.97-62.19-43.68-194.97-259.83-458.55-771.86-1,132.08
EPS (Diluted)-9.33-6.97-62.19-43.68-194.97-259.83-458.55-771.86-1,132.08
EBITDA-35.93-35.93-27.10-33.25-23.26-15.27-6.96-3.58-4.69
Non-Operating Income (Expense)0.230.32-0.130.160.850.11-2.170.010.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.741.740.781.802.193.071.970.000.05
Shares Outstanding8.718.711.880.120.110.100.100.000.00
Market Capitalization31.3532.2214.0513.7611.75----

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.030.030.030.030.03
Gross Profit-0.03-0.03-0.03-0.03-0.03-0.03-0.03-0.03
Selling, General and Administrative Excl. Other12.557.597.508.308.536.307.145.13
Research and Development10.505.946.036.667.114.815.683.67
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-12.58-7.62-7.53-8.32-8.55-6.33-7.17-5.15
Interest Expense0.000.000.000.000.000.040.000.00
Unusual Expense-0.00-0.26-0.21-0.02-0.45-0.18-0.810.62
Net Income Before Taxes-12.51-7.24-7.30-8.28-8.16-6.22-6.34-5.83
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.51-7.24-7.30-8.28-8.16-6.22-6.34-5.83
Net Income From Continuing Operations-12.32-7.16-7.22-8.20-8.09-6.13-6.29-5.80
Net Income-12.32-7.16-7.22-8.20-8.09-6.13-6.29-5.80
EPS (Recurring)-1.41-1.01-2.63-4.36-4.46-16.73-25.40-30.24
EPS (Basic, Before Extraordinaries)-1.41-0.99-2.58-4.35-4.29-16.40-23.31-32.67
EPS (Diluted)-1.41-0.99-2.58-4.35-4.29-16.40-23.31-32.67
EBITDA-12.55-7.59-7.50-8.30-8.53-6.30-7.14-5.13
Non-Operating Income (Expense)0.060.120.020.02-0.06-0.040.02-0.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.720.430.290.290.000.220.290.27
Shares Outstanding8.717.257.251.881.880.660.290.24
Market Capitalization31.3530.3126.7120.7214.0529.2514.7929.42

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments20.5417.870.8621.2541.0457.270.020.151.75
Short Term Receivables0.000.561.370.020.020.010.020.000.01
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.501.501.425.681.280.520.200.010.11
Total Current Assets22.0419.933.6526.9542.3557.800.240.161.88
Net Property, Plant & Equipment0.320.300.390.000.000.000.000.000.00
Total Investments and Advances0.730.520.422E-062E-062E-060.000.000.00
Intangible Assets0.170.180.200.220.230.250.240.260.27
Other Assets0.320.721.210.000.000.000.000.000.13
Total Assets23.5821.655.8727.1642.5858.040.480.422.29
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.000.230.301.12
Accounts Payable6.993.287.170.000.000.000.000.000.00
Other Current Liabilities0.990.690.291.800.940.563.410.760.22
Total Current Liabilities7.983.987.461.800.940.563.641.061.34
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.040.341.1029.1431.3129.820.000.000.00
Total Liabilities8.024.328.5630.9432.2530.373.641.061.34
Non-Equity Reserves0.000.000.000.000.000.000.140.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity16.4017.88-2.38-3.7810.3327.67-3.30-0.640.95
Total Shareholders Equity16.4017.88-2.38-3.7810.3327.67-3.30-0.640.95
Accumulated Minority Interest-0.84-0.55-0.300.000.000.000.000.000.00
Total Equity15.5617.33-2.68-3.7810.3327.67-3.30-0.640.95
Total Liabilities & Stockholders Equity23.5821.655.8727.1642.5858.040.480.422.29
Book Value Per Share1.889.49-19.54-35.4599.84271.83-685.52-147.65267.82
Tangible Book Value Per Share1.869.39-21.18-37.4797.61269.42-735.23-206.85189.96
Full-Time Employees311718128666-
Price to Book Ratio1.960.79-5.78-1.97-----
Return on Assets-154.34-191.21-29.01-58.22-53.35-47.22-820.85-323.78-216.95
Return on Equity-203.63-339.54--619.75-79.42-113.38--2,903.92-501.86
Return on Invested Capital-212.82-147.15---259.84-49.93---449.33
Quick Ratio2.765.010.4914.9645.00103.810.070.151.40
Current Ratio2.765.010.4914.9645.00103.810.070.151.40

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-35.05-35.33-26.56-4.93-20.30-26.84-13.82-3.67-4.38
Depreciation0.120.120.110.080.020.020.020.010.01
Other Funds (Non Cash)1.581.590.19-26.330.0714.738.330.07-0.27
Funds from Operations-33.35-33.61-26.26-31.18-20.21-12.09-5.47-3.59-4.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.924.96-1.917.05-3.53-0.39-2.282.440.78
Cash from Operating Activities-28.43-28.65-28.17-24.13-23.74-12.48-7.75-1.16-3.85
Capital Expenditures-0.13-0.130.00-0.460.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-3.65-3.68-7.65-0.230.000.000.000.001.01
Purchase of Investments-24.77-24.97-7.65-0.230.000.000.000.000.00
Sale Or Maturity of Investments21.1321.290.000.000.000.000.000.001.01
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-3.78-3.81-7.65-0.680.000.000.000.001.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock31.5731.8145.454.423.95-3.7265.331.052.26
Repurchase of Common Pref Stock0.000.000.000.00-0.05-10.170.000.000.00
Sale of Common Pref Stock31.5731.8145.454.424.006.4565.331.052.26
Proceedsfrom Stock Options31.5731.8144.630.000.00-0.0651.621.052.16
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-0.330.020.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.020.000.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.020.000.000.00
Cash from Financing Activities31.5731.8145.454.423.95-3.7465.001.072.26
Exchange Rate Effect------0.00-0.040.01
Net Change in Cash-0.64-0.649.63-20.39-19.79-16.2357.25-0.12-0.56
Free Cash Flow-28.56-28.78-28.17-24.58-23.74-12.48-7.75-1.16-3.85
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments20.5422.8029.9010.1817.8712.46
Short Term Receivables0.002.592.280.000.560.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.500.000.001.171.502.32
Total Current Assets22.0425.3932.1811.3519.9314.79
Net Property, Plant & Equipment0.320.350.250.270.300.32
Total Investments and Advances0.730.750.580.550.520.50
Intangible Assets0.170.170.180.180.180.19
Other Assets0.320.410.410.720.721.21
Total Assets23.5827.0733.5913.0821.6517.00
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable6.990.000.000.003.280.00
Other Current Liabilities0.993.593.193.320.694.33
Total Current Liabilities7.983.593.193.323.984.33
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.040.070.200.410.340.73
Total Liabilities8.023.663.383.724.325.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.4024.0630.929.9817.8812.42
Total Shareholders Equity16.4024.0630.929.9817.8812.42
Accumulated Minority Interest-0.84-0.65-0.70-0.63-0.55-0.47
Total Equity15.5623.4130.219.3517.3311.94
Total Liabilities & Stockholders Equity23.5827.0733.5913.0821.6517.00
Book Value Per Share1.883.324.265.309.4918.93
Tangible Book Value Per Share1.863.294.245.209.3918.64
Full-Time Employees31---17-
Price to Book Ratio1.910.980.811.160.792.36
Return on Assets-154.34-139.20-137.98-244.43-191.21-167.50
Return on Equity-203.63-168.21-171.72-409.50-339.54-602.61
Return on Invested Capital-75.12-29.78-23.36-82.16-45.25-49.35
Quick Ratio2.767.0710.103.425.013.41
Current Ratio2.767.0710.103.425.013.41

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income-12.05-7.43-7.30-8.28-8.82-6.20
Depreciation0.030.030.030.030.030.03
Other Funds (Non Cash)0.940.100.230.32-0.390.11
Funds from Operations-11.08-7.29-7.04-7.93-9.18-6.06
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.530.09-0.920.230.35-1.07
Cash from Operating Activities-5.55-7.21-7.97-7.70-8.84-7.13
Capital Expenditures0.00-0.130.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments5.09-15.957.28-0.07-7.51-0.10
Purchase of Investments-8.60-16.01-0.09-0.07-7.51-0.10
Sale Or Maturity of Investments13.690.067.370.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.09-16.087.28-0.07-7.51-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.470.2327.870.0014.6914.60
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.470.2327.870.0014.6914.60
Proceedsfrom Stock Options3.470.2327.870.0014.6614.59
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.470.2327.870.0014.6914.60
Net Change in Cash3.01-23.0527.19-7.78-1.667.36
Free Cash Flow-5.55-7.34-7.97-7.70-8.84-7.13

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.26%0.8M8.7M264.00K
2026-10-159.09%0.8M8.7M264.73K
2026-09-308.97%0.8M8.7M297.41K
2026-09-159.41%0.8M8.4M282.60K
2026-08-318.60%0.7M8.4M307.17K
2026-08-144.74%0.4M8.4M196.43K
2026-07-314.85%0.4M8.4M195.93K
2026-07-155.20%0.4M8.6M218.70K
2026-06-304.43%0.4M8.6M197.88K
2026-06-154.39%0.4M8.6M216.16K
2026-05-2910.11%0.9M8.6M219.16K
2026-05-156.58%0.5M7.2M206.02K
2026-04-306.61%0.5M7.2M194.93K
2026-04-153.18%0.2M7.2M276.42K
2026-03-313.96%0.3M7.1M497.34K
2026-03-132.04%0.1M7.1M470.88K
2026-02-271.46%0.1M7.1M430.37K
2026-02-131.42%0.1M7.2M411.10K
2026-01-302.32%0.1M6.1M386.21K
2026-01-150.72%0.0M6.1M290.68K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-2810-KAnnual report pursuant to Section 13 or 15(d)2026-07-31SEC
2026-06-268-KCurrent report2026-06-26SEC
2026-06-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-04-30SEC
2026-06-038-KCurrent report2026-05-31SEC
2026-06-02424B5SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-01-31SEC
2026-03-098-KCurrent report2026-03-05SEC
2026-02-2625-NSESEC
2026-02-208-KCurrent report2026-02-18SEC
2026-02-12DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-02-12SEC
2026-01-23SCHEDULE 13GSEC
2026-01-158-KCurrent report2026-01-13SEC
2026-01-14424B4SEC
2026-01-13EFFECTEffectiveness filing by commission orderSEC
2026-01-13S-1MEFA new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1SEC
2026-01-138-A12BSEC
2026-01-13CERTSEC
2026-01-08CORRESPSEC
2026-01-08CORRESPSEC
2026-01-06CORRESPSEC
2026-01-06CORRESPSEC
2025-12-298-KCurrent report2025-12-29SEC
2025-12-23FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2025-12-23S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2025-12-1110-QQuarterly report pursuant to Section 13 or 15(d)2025-10-31SEC
2025-12-018-KCurrent report2025-11-28SEC
2025-11-07SCHEDULE 13G/ASEC
2025-10-16DRSLTRCorrespondence Submission of a DRS filer. Correspondence is not publicly disseminated immediately. The SEC staff may publicly release all or portions of these documents.SEC
2025-10-16DRSSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Cable Car Capital, LP2.49%
SABBY MANAGEMENT, LLC0.93%
IRIDIAN ASSET MANAGEMENT LLC/CT0.75%
HRT FINANCIAL LP0.40%
JANE STREET GROUP, LLC0.30%
LuminArx Capital Management LP0.17%
NATIONAL BANK OF CANADA /FI/0.02%
MORGAN STANLEY0.01%
Federation des caisses Desjardins du Quebec0.01%
UBS Group AG0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. BCTX. Cached 15 minutes.

Some panels did not load: insider.